article thumbnail

Biosimilar competition saves US healthcare $21 billion

European Pharmaceutical Review

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. More interchangeable biosimilars are estimated to be approved and launched in the US in the next few years.

article thumbnail

Is the launch environment really more competitive now?

pharmaphorum

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. A second, “transitional era” from 2000-2015 was one of older specialty products, including those in multiple sclerosis, early immunological biologics, and oncologics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). We have in front of us a unique opportunity to not only appreciate but harness the power of generational diversity as a competitive advantage.

article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

Many drug companies spent a significant portion of their R&D budget on finding ways to suppress generic and biosimilar competition while continuing to raise prices, rather than on innovative research. In a 2015 study of 36 cancer drugs that had recently been approved, only 5 showed extended life. Big pharma is big business.

Pharma 292
article thumbnail

Collaborations between pharma and academia increase

European Pharmaceutical Review

According to the survey, apprentice numbers are three times higher than 2015 statistics, across all skill levels from those entering the industry to master-qualified individuals. Pharmaceutical companies who contributed to the survey include AbbVie, AstraZeneca, Boehringer Ingelheim and GSK.

Pharma 104
article thumbnail

Novartis knocked back again in bid to block Gilenya generics in US

pharmaphorum

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. 9,187,405, granted in 2015, which covers a specific dosing regimen for Gilenya (fingolimod) in relapsing-remitting MS. Gilenya made revenues of $2.8

article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

China will continue to take steps towards becoming as competitive in high-value innovative pharma as it is in the generics industry, with The Wall Street Journal reporting Chinese biotechs raised $1.6tn through 568 venture financings last year, up from $11bn in 418 deals in 2020.